Fluorodopa scan for congenital hyperinsulinism and insulinoma
Part of Cancer, Digestive system, Genetic & congenital, Hormones & metabolism clinical trials.
This Phase 1 study tests a special imaging medicine (fluorodopa F 18) to help doctors better understand congenital hyperinsulinism (HI) patterns in the body. It may help guide treatment decisions to prevent dangerous low blood sugar and protect brain function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have a confirmed diagnosis of congenital hyperinsulinism (HI)
- Your HI specialist doctor must say standard medicines are not enough and surgery is recommended
- Low blood sugar must have happened despite treatment, or fasting is not safe (can’t stay above 50 mg/dL for the required time)
- Genetic test results should not clearly show a diffuse (widespread) HI type, or genetic results may be missing/negative
- You must not be pregnant, and breastfeeding plans must allow stopping for 48 hours after the injection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study uses an FDOPA PET scan to find where insulin overproduction is coming from in focal congenital hyperinsulinism (FoHI) or related conditions. The goal is to help doctors better detect and localize the “source” so treatment can be more targeted.
This study uses a special PET scan to find areas in the pancreas that are making too much insulin, which can cause low blood sugar. The scan may help doctors plan surgery to remove these spots and improve blood sugar control.
This trial improves a special PET scan (a type of brain/body imaging) using 18F-DOPA, to better show how certain conditions behave in the body. If you or your child may have one of the listed conditions, the study may help your doctors get clearer scan results.
This trial compares two similar PET/CT scan agents to see which one better finds insulinomas — small tumors in the pancreas that cause low blood sugar. If you're scheduled for surgery, the results might help your doctor pinpoint the tumor before the operation.
This Phase 2 study uses special PET/MRI imaging to better understand a cause of hyperinsulinemic low blood sugar and guide whether surgery may help. It may help doctors choose the safest plan to reduce severe episodes and protect the brain.
This trial tests whether a new imaging agent called FMISO can help see areas of low oxygen in brain tumors. It may help doctors better target treatment for gliomas.
Hear when a new Congenital Hyperinsulinism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.